NVN Liquidation, Inc. (0A4P.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 06:31PM BST. Market open.
| Previous close | 0.0008 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 425 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8930 |
| Earnings date | 23 Apr 2024 - 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Thomson Reuters StreetEvents
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
ZacksLigand (LGND) Acquires Certain Assets of Novan for $12.2M
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
ZacksLigand (LGND) Offers $15M in Cash to Acquire All Novan Assets
Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.
© 2024 Yahoo. All rights reserved.